Resurrection of PARP inhibitors in breast cancer Journal Article
| Authors: | Lyons, T. G.; Robson, M. E. |
| Article Title: | Resurrection of PARP inhibitors in breast cancer |
| Abstract: | PARP enzymes are essential for DNA damage repair. Cancers with defective homologous recombination DNA repair, such has BRCA1- and BRCA2-mutated breast cancers, are targets for PARP inhibitors (PARPi) through the exploitation of synthetic lethality. A number of PARPi are currently undergoing clinical evaluation in breast cancer, with olaparib and talazoparib having demonstrated superior efficacy compared with standard chemotherapy in advanced germline BRCA-mutated cancer. This review describes the biological rationale for PARPi and presents the accumulating data on PARPi use in breast cancer. © JNCCN—Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 16 |
| Issue: | 9 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2018-09-01 |
| Start Page: | 1150 |
| End Page: | 1156 |
| Language: | English |
| DOI: | 10.6004/jnccn.2018.7031 |
| PROVIDER: | scopus |
| PUBMED: | 30181424 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 October 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work